Luigi Auletta

Prof. Luigi Auletta

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Theriogenology
Verified
Journal Article
Closed access
NCNatascia Cocchia
Natascia Cocchia
OPOrlando Paciello
Orlando Paciello
Luigi AulettaLuigi Auletta
Luigi Auletta
VUValeria Uccello
Valeria Uccello
LSLaura Silvestro
Laura Silvestro
MPMaria Pia Pasolini
Maria Pia Pasolini

1 January 2017 in Theranostics
Verified
Journal Article
Open access
Simona CamoraniSimona Camorani
Simona Camorani
BHBilly Samuel Hill
Billy Samuel Hill
RFRaffaela Fontanella
Raffaela Fontanella
AGAdelaide Greco
Adelaide Greco
MGMatteo Gramanzini
Matteo Gramanzini
AZAntonella Zannetti
Antonella Zannetti
Bone marrow-derived mesenchymal stem cells (BM-MSCs) are shown to participate in tumor progression by establishing a favorable tumor microenvironment (TME) that promote metastasis through a cytokine networks. However, the mechanism of homing and recruitment of BM-MSCs into tumors and their potential role in malignant tissue progression is poorly understood and controversial. Here we show that BM-MSCs increase aggressiveness of triple-negative breast cancer (TNBC) cell lines evaluated as capability to migrate, invade and acquire stemness markers. Importantly, we demonstrate that the treatment of BM-MSCs with a nuclease-resistant RNA aptamer against platelet-derived growth factor receptor β (PDGFRβ) causes the inhibition of receptor-dependent signaling pathways thus drastically hampering BM-MSC recruitment towards TNBC cell lines and BM-MSCs trans-differentiation into carcinoma-associated fibroblast (CAF)-like cells. Moreover, in vivo molecular imaging analysis demonstrated the aptamer ability to prevent BM-MSCs homing to TNBC xenografts. Collectively, our results indicate the anti-PDGFRβ aptamer as a novel therapeutic tool to interfere with BM-MSCs attraction to TNBC providing the rationale to further explore the aptamer in more complex pre-clinical settings.

22 July 2021 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
LALisa Agnello
Lisa Agnello
STSilvia Tortorella
Silvia Tortorella
ADAnnachiara D’aRgenio
Annachiara D’aRgenio
CCClarissa Carbone
Clarissa Carbone
Simona CamoraniSimona Camorani
Simona Camorani
Laura CerchiaLaura Cerchia
Laura Cerchia
Background: Management of triple-negative breast cancer (TNBC) is still challenging because of its aggressive clinical behavior and limited targeted treatment options. Cisplatin represents a promising chemotherapeutic compound in neoadjuvant approaches and in the metastatic setting, but its use is limited by scarce bioavailability, severe systemic side effects and drug resistance. Novel site-directed aptamer-based nanotherapeutics have the potential to overcome obstacles of chemotherapy. In this study we investigated the tumor targeting and the anti-tumorigenic effectiveness of novel cisplatin-loaded and aptamer-decorated nanosystems in TNBC. Methods: Nanotechnological procedures were applied to entrap cisplatin at high efficacy into polymeric nanoparticles (PNPs) that were conjugated on their surface with the epidermal growth factor receptor (EGFR) selective and cell-internalizing CL4 aptamer to improve targeted therapy. Internalization into TNBC MDA-MB-231 and BT-549 cells of aptamer-decorated PNPs, loaded with BODIPY505-515, was monitored by confocal microscopy using EGFR-depleted cells as negative control. Tumor targeting and biodistribution was evaluated by fluorescence reflectance imaging upon intravenously injection of Cyanine7-labeled nanovectors in nude mice bearing subcutaneous MDA-MB-231 tumors. Cytotoxicity of cisplatin-loaded PNPs toward TNBC cells was evaluated by MTT assay and the antitumor effect was assessed by tumor growth experiments in vivo and ex vivo analyses. Results: We demonstrate specific, high and rapid uptake into EGFR-positive TNBC cells of CL4-conjugated fluorescent PNPs which, when loaded with cisplatin, resulted considerably more cytotoxic than the free drug and nanovectors either unconjugated or conjugated with a scrambled aptamer. Importantly, animal studies showed that the CL4-equipped PNPs achieve significantly higher tumor targeting efficiency and enhanced therapeutic effects, without any signs of systemic toxicity, compared with free cisplatin and untargeted PNPs. Conclusions: Our study proposes novel and safe drug-loaded targeted nanosystems for EGFR-positive TNBC with excellent potential for the application in cancer diagnosis and therapy.

2 April 2022 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ASAnnachiara Sarnella
Annachiara Sarnella
YFYlenia Ferrara
Ylenia Ferrara
Luigi AulettaLuigi Auletta
Luigi Auletta
SASandra Albanese
Sandra Albanese
Laura CerchiaLaura Cerchia
Laura Cerchia
AZAntonella Zannetti
Antonella Zannetti
Background: Hypoxic tumor microenvironment (TME) contributes to the onset of many aspects of the cancer biology associated to the resistance to conventional therapies. Hypoxia is a common characteristic and negative prognostic factor in the head and neck squamous carcinomas (HNSCC) and is correlated with aggressive and invasive phenotype as well as with failure to chemo- and radio-therapies. The carbonic anhydrase isoenzymes IX and XII (CA IX/XII), regulators of extra and intracellular pH, are overexpressed in TME and are involved in adaptative changes occurring in cancer cells to survive at low O2. In this study, we aim to investigate in HNSCC cells and murine models the possibility to target CA IX/XII by the specific inhibitor SLC-0111 to potentiate the effects of cisplatin in hampering cell growth, migration and invasion. Furthermore, we analyzed the signal pathways cooperating in acquisition of a more aggressive phenotype including stemness, epithelial-mesenchymal transition and apoptotic markers. Methods: The effects of cisplatin, CA IX/XII specific inhibitor SLC-0111, and the combinatorial treatment were tested on proliferation, migration, invasion of HNSCC cells grown in 2D and 3D models. Main signal pathways and the expression of stemness, mesenchymal and apoptotic markers were analyzed by western blotting. Molecular imaging using NIR-Annexin V and NIR-Prosense was performed in HNSCC xenografts to detect tumor growth and metastatic spread. Results: HNSCC cells grown in 2D and 3D models under hypoxic conditions showed increased levels of CA IX/XII and greater resistance to cisplatin than cells grown under normoxic conditions. The addition of CA IX/XII inhibitor SLC-0111 to cisplatin sensitized HNSCC cells to the chemotherapeutic agent and caused a reduction of proliferation, migration and invasiveness. Furthermore, the combination therapy hampered activation of STAT3, AKT, ERK, and EMT program, whereas it induced apoptosis. In HNSCC xenografts the treatment with cisplatin plus SLC-0111 caused an inhibition of tumor growth and an induction of apoptosis as well as a reduction of metastatic spread at a higher extent than single agents. Conclusion: Our results highlight the ability of SLC-0111 to sensitize HNSCC to cisplatin by hindering hypoxia-induced signaling network that are shared among mechanisms involved in therapy resistance and metastasis.

1 July 2015 in Journal of Comparative Pathology
Verified
Journal Article
Closed access
SMSerena Montagnaro
Serena Montagnaro
CMC. De Martinis
C. De Martinis
SSS. Sasso
S. Sasso
RCR. Ciarcia
R. Ciarcia
SDS. Damiano
S. Damiano
UPU. Pagnini
U. Pagnini

4 August 2017 in Parasitology Research
Verified
Journal Article
Closed access
PDF file
DPDiego Piantedosi
Diego Piantedosi
BNBenedetto Neola
Benedetto Neola
NDNicola D’alessio
Nicola D’alessio
FPFrancesca Di Prisco
Francesca Di Prisco
MSMario Santoro
Mario Santoro
VVVincenzo Veneziano
Vincenzo Veneziano